Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $258.00 Price Target at Royal Bank Of Canada

Key Points

• Royal Bank of Canada raised its price target on Jazz to $258 (from $195) and kept an "outperform" rating, implying roughly a 15.3% upside from the prior close.
• Jazz delivered a sizable Q1 EPS beat ($6.34 vs. ~ $4.67 consensus) and management noted ~19% year‑over‑year revenue growth with strength in Xywav and Epidiolex, helping lift the stock.
• The pipeline has a near‑term binary: zanidatamab received Priority Review with a PDUFA date of August 25, 2026, which could materially affect long‑term revenues if approved.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price objective hoisted by stock analysts at Royal Bank Of Canada from $195.00 to $258.00 in a report released on Wednesday,Benzinga reports. The firm currently has an "outperform" rating on the specialty pharmaceutical company's stock. Royal Bank Of Canada's price objective would indicate a potential upside of 15.27% from the company's previous close.

Other research analysts have also recently issued reports about the company. Leerink Partners upped their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 22nd. Piper Sandler boosted their price objective on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an "overweight" rating in a research report on Thursday, March 19th. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an "overweight" rating in a research report on Wednesday. Needham & Company LLC boosted their price target on shares of Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a "buy" rating in a research report on Monday, January 12th. Finally, Truist Financial upgraded Jazz Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $225.53.

Jazz Pharmaceuticals Trading Up 5.4%

Shares of NASDAQ:JAZZ traded up $11.56 during midday trading on Wednesday, hitting $223.82. The company had a trading volume of 902,096 shares, compared to its average volume of 998,499. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals has a 12 month low of $97.50 and a 12 month high of $230.40. The firm has a fifty day simple moving average of $190.45 and a 200 day simple moving average of $171.65. The stock has a market cap of $14.04 billion, a price-to-earnings ratio of -37.51, a PEG ratio of 0.36 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. On average, analysts predict that Jazz Pharmaceuticals will post 20.51 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the transaction, the director directly owned 384,682 shares of the company's stock, valued at $73,281,921. This trade represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,015 shares of company stock valued at $14,180,486 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 234 shares during the period. Hilltop National Bank bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $36,000. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth about $38,000. Danske Bank A S bought a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter valued at about $40,000. Finally, Quent Capital LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $44,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Large EPS beat - Jazz reported $6.34 EPS vs. consensus ~$4.67, a sizeable upside that drove investor enthusiasm for profitability and cash-generation potential. Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Pipeline catalyst — zanidatamab (HER2+ 1L GEA) received Priority Review with a PDUFA date of Aug 25, 2026, creating a clear near-term binary that could materially affect long-term revenues if approved. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Positive Sentiment: Commercial growth — management highlighted ~19% YoY revenue growth and product-level strength (Xywav and Epidiolex growth; net patient adds), supporting the view that core franchises are expanding. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: Guidance reaffirmed — the company reiterated 2026 revenue and expense guidance, which reduces uncertainty but leaves investors waiting for full-year detail and cadence. Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
• Neutral Sentiment: More detail available — the earnings call transcript and slide deck provide management color on growth drivers and cost assumptions for 2026; useful for modeling but not an immediate directional news item. Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Top-line slightly missed Street revenue consensus (reported ~$975M vs. ~$978M estimate), which tempers the beat and suggests some near-term sales variability. Jazz Pharmaceuticals Q1 Results Summary
• Negative Sentiment: GAAP profitability and margins — the company still reported a negative net margin and modest ROE; investors should watch how one-time items, R&D and SG&A trends affect sustained profitability. Jazz Pharmaceuticals Q1 Results Summary

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.